[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infertility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infertility":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,145,0,25,[9,51,88,116,145,170,193,227,256,277,298,328,348,379,400,422,442,473,493,514,550,573,596,626,660],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100652335","ovarian-stromal-stiffness-and-ovarian-reserve-parameters-via-transvaginal-shear-wave-elastography-100652335",false,"NCT07773337","Ovarian Stromal Stiffness and Ovarian Reserve Parameters Via Transvaginal Shear Wave Elastography","Relationship Between Ovarian Stromal Stiffness Measured by Transvaginal Shear Wave Elastography and Hormonal and Ultrasonographic Ovarian Function Parameters","Inclusion Criteria:\n\n* Female patients aged 18 to 45 years.\n* Regular menstrual cycles (21-35 days) or irregular menstruel cycles (oligo-anovaltion)\n* Normal pelvic anatomy on baseline ultrasound evaluation.\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* History of prior ovarian or adnexal surgery.\n* History of pelvic radiotherapy or chemotherapy.\n* Presence of structural pelvic\u002Fovarian pathology (e.g., endometrioma, ovarian cyst, dermoid cyst, active pelvic inflammatory disease).\n* Use of hormonal contraceptives, ovulation induction agents, or hormone therapy within the last 3 months.\n* Pregnancy or current lactation.\n* Severe obesity or technical limitations preventing adequate transvaginal ultrasound and elastography imaging",true,"FEMALE","18 Years","45 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to evaluate the relationship between ovarian stromal stiffness measured by transvaginal shear wave elastography (SWE) and conventional hormonal and ultrasonographic parameters of ovarian reserve. Reproductive-aged female patients will be evaluated to determine whether tissue elasticity provided by SWE correlates with ovarian function markers such as anti-Müllerian hormone (AMH), antral follicle count (AFC), and ovarian volume.",[29,30,31,32],"Ovarian Reserve Markers","Ovarian Function","Infertility","Anovulatory",[34,35,36,37],"Shear Wave Elastography","Transvaginal Ultrasound","Ovarian Stroma","Anti-Mullerian Hormone","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":23},"2026-08",{"date":46,"type":23},"2026-12-01",{"name":48,"class":49},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100620503","impact-of-fet-preparation-protocol-on-endometrial-peristalsis-a-prospective-cohort-study-100620503","NCT07358468","Association Between Peri-Transfer Endometrial Peristalsis And Live Birth In Modified Natural Cycle Frozen Embryo Transfer: A Prospective Cohort Study","Effects Of Modified Natural Cycle Protocol Peristalsis And Live Birth In Frozen Embryo Transfer: A Prospective Cohort Study","EPFE","Inclusion Criteria:\n\n* Women aged 18 - 42 years old\n* Scheduled for frozen embryo transfer cycles using hormone replacement therapy protocol or natural cycle protocol (True natural cycles or modified natural cycles)\n* Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts\n\nExclusion Criteria:\n\n* Having an allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Cycles with preimplantation genetic testing, oocyte donation, or in vitro maturation\n* Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus, endometrial polyp, large leiomyoma ≥5 cm in diameter, hydrosalpinx, endometrial hyperplasia).\n* Use of uterine relaxants or intralipid infusion during the embryo transfer process.\n* Use of a GnRH-agonist for downregulation within one month.\n* PCOS patients","42 Years",{"count":61,"type":23},384,"OBSERVATIONAL","The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive treatments. Endometrial peristalsis refers to the frequency, amplitude, and pattern of myometrial contractions occurring in different reproductive phases. These peristalsis play vital roles in sperm transport, embryo migration, and implantation. Clinical and imaging studies suggest that abnormal patterns or excessive contractility at the time of embryo transfer may disrupt endometrial-embryo synchrony, impair implantation, and increase miscarriage risk. However, most evidence on endometrial peristalsis pertains to fresh embryo transfer cycles, natural conceptions, or pathological contexts, such as adenomyosis or fibroids, with limited insights regarding its effects on different endometrial preparation protocols in frozen embryo transfer (FET). Understanding the dynamics of endometrial peristalsis in this context is clinically important, as inappropriate contractile activity could physically expel the embryo or create a non-receptive environment, ultimately reducing the chances of live birth. Despite its theoretical significance, there is a paucity of robust, prospective data correlating endometrial peristalsis patterns measured around the time of FET with different endometrial preparation protocols with subsequent pregnancy outcomes.",[31,65,66,67,68,69],"Endometrial Peristalsis","Uterine Contraction","Endometrial Waves","Frozen Embryo Transfer (FET)","Uterine Peristalsis",[71,72,73,74,75,76],"endometrial peristalsis","uterine contractions","endometrial waves","frozen embryo transfer","natural cycles","artificial cycles","RECRUITING","2026-08-17",{"date":80,"type":42},"2026-08-19",{"date":82,"type":42},"2026-02-22",{"date":84,"type":23},"2027-12-01",{"name":86,"class":49},"Mỹ Đức Hospital",2,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":50},"100473109","biorepository-in-participants-who-undergo-otc-for-gonadotoxic-therapy-100473109","NCT05440617","Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent\u002Fassent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Subjects who have planned to undergo OTC for gonadotoxic therapy based on current standard of care.\n\nEXCLUSION CRITERIA:\n\n-An individual who meets any of the following criteria will be excluded from participation in this study:\n\n--Adults subjects with psychological, psychiatric, or other conditions which prevent giving fully informed consent.","4 Years","35 Years",{"count":22,"type":23},"Background:\n\nMedical advances have improved survival rates for many cancers and other illnesses. This means that more people are coping with the long-term effects of these treatments. Some treatments can cause female infertility. Ovarian tissue cryopreservation (OTC) may help. Before undergoing a treatment that may damage their fertility, patients may opt to freeze a sample of ovarian tissue. The tissue contains immature egg cells. When thawed, the tissue can be reimplanted. This procedure can help women become pregnant.\n\nObjective:\n\nThis natural history study will create a databank of ovarian tissue. The NIH will provide OTC as a clinical service. The NIH will also request a portion of the tissue to use for research.\n\nEligibility:\n\nFemales aged 4 to 35 who opt to have OTC before receiving cancer treatment.\n\nDesign:\n\nParticipants will be screened. Their existing medical records will be reviewed.\n\nThey will be asked if they want to donate a portion of their ovarian tissue for research. No more than 20% of the tissue collected will be taken for research. Some other tissues that would otherwise be discarded will also be kept.\n\nMedical data from each participant may also be collected and stored in the database. This data may include results of routine blood tests, imaging tests, and other information. The data will be coded for privacy.\n\nParticipants will answer a questionnaire. They will be asked about their fertility treatment and general health. The survey takes about 30 minutes.\n\nThey will repeat the questionnaire once a year for 30 years.\n\n...",[99,31,100],"Acute Ovarian Failure","Early Menopause And Infertility In Females After Treatment For Childhood Cancer",[102,103,104,105,106],"Ovarian Tissue Preservation","Cancer Survivors And Infertility","Acute Ovarian Failure In The Childhood Cancer Survivor Study","Ovarian Failure After Radiation","Natural History","2026-08-15",{"date":39,"type":42},{"date":110,"type":42},"2022-07-22",{"date":112,"type":23},"2041-09-21",{"name":114,"class":115},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":62,"phases":4,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":50},"100595752","non-euploid-embryo-transfer-neet-registry-100595752","NCT07036536","Non-Euploid Embryo Transfer (NEET) Registry","The NEET Registry: a Prospective, Observational Study for Outcomes of Non-euploid Embryo Transfers (NEET)","Inclusion Criteria:\n\n* Patient is planning a non-euploid embryo transfer (NEET) at a fertility clinic in The Prelude Network.\n* Patient has signed informed consent to participate in the registry.\n\nExclusion Criteria:\n\n* Not applicable",{"count":124,"type":23},1000,"5 Years","The NEET Registry is a registry to track and study the outcomes of non-euploid embryo transfers (NEET) in The Prelude Network",[31,128,129],"Mosaicism","Aneuploidy",[131,132,133,134],"IVF","PGT-A","aneuploid","FET","2026-08-13",{"date":137,"type":42},"2026-08-14",{"date":139,"type":42},"2024-09-23",{"date":141,"type":23},"2030-12",{"name":143,"class":144},"Inception Fertility Research Institute, LLC","INDUSTRY",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":154,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100619146","a-study-to-compare-the-efficacy-and-safety-of-follitropin-alfalutropin-alfa-versus-hmg-in-japanese-participants-with-lh-and-fsh-deficiency-undergoing-art-hinata-100619146","NCT07340827","A Study to Compare the Efficacy and Safety of Follitropin Alfa\u002FLutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","A Parallel-group Treatment, 2-arm Study to Compare the Efficacy and Safety of Follitropin Alfa and Lutropin Alfa Fixed Dose Combination Versus hMG for Inducing Follicular Development in Japanese Participants With LH and FSH Deficiency Undergoing ART","Inclusion Criteria:\n\n* Participants who are premenopausal wishing to conceive\n* Participants with maximum 1 previous stimulation for assisted reproductive technology (ART) without pregnancy\n* Japanese Participants\n* Participants are women with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency congenital or acquired\n* Participants have a vaginal ultrasound scan showing both ovaries and no clinically significant uterine abnormality and a normal antral follicle count (AFC) of at least 5 follicles 2 to 10 millimeter (mm) in diameter per ovary\n* A semen analysis of the male partner been performed within 3 months prior to signature of informed consent and suitable for assisted reproductive technology\n* Participants have a normal cervical ThinPrep® cytologic test, (TCT) or Pap smear within 12 months of Screening. If not available, a cervical smear will be performed as part of screening\n* Other protocol defined criteria may apply\n\nExclusion Criteria:\n\n* Participants with history of severe OHSS in any previous ovarian stimulation cycle\n* Participants with Polycystic ovarian syndrome (PCOS) according to Rotterdam modified definition\n* Participants with contraindication to treatment with gonadotropins, hypersensitivity to gonadotropins or to any of the excipients\n* Participants with presence of known or suspected gonadotropin- or estrogen dependent malignancy (example. ovarian-, uterine-, or mammary carcinoma)\n* Participants with ovarian enlargement or cyst of unknown etiology, or presence of an ovarian cyst greater than 25 millimeters before Day 1\n* other protocol defined exclusion criteria may apply",{"count":153,"type":23},266,[155],"PHASE3","The purpose of this study is to assess the efficacy and safety of follitropin alfa\u002Flutropin alfa in Japanese participants with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency undergoing Assisted reproductive technology (ART).\n\nThe study duration is approximately 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy in Part A.",[31],[159],"Gonadotropins, infertility, prefilled pen","2026-08-07",{"date":162,"type":42},"2026-08-10",{"date":164,"type":42},"2026-02-04",{"date":166,"type":23},"2028-07-05",{"name":168,"class":144},"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",21,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":50},"100610340","early-phase-1-the-hysterosalpingogram-hsg-experience-and-tubal-spasm-heat-study-100610340","NCT07226310","The Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study","The Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study: A Randomized Controlled Trial","HEAT","Inclusion Criteria:\n\n1\\. Women ages 18-45 undergoing tubal assessment via HSG.\n\nExclusion Criteria:\n\n1. History of fibroids\n2. History of pelvic inflammatory disease (PID or STD including gonorrhea, chlamydia, or trichomonas)\n3. History of surgically diagnosed endometriosis or suspected endometriosis on ultrasound (indicated by visualization of likely endometrioma)\n4. History of ectopic pregnancy or 3 or more biochemical pregnancies\u002Fpregnancy of unknown location\n5. History of tubal or ovarian surgery\n6. History of known Mullerian anomaly\n7. History of pelvic surgery including appendectomy\n8. Allergy to iodine-based contrast media\n9. History of prior abnormal fallopian tubes on HSG\n10. History of ultrasound with hydrosalpinx (unilateral or bilateral)",{"count":179,"type":23},240,[181],"EARLY_PHASE1","The hysterosalpingogram (HSG) is the gold standard of assessing fallopian tube patency and involves the placement of a transcervical catheter to allow for instillation of radio-opaque dye into the uterine cavity and fallopian tubes which are then imaged with abdominal x-ray. A common side effect of the instillation of dye is the uterine cramping, which is both uncomfortable for the patient as well as can cause iatrogenic proximal occlusion of the fallopian tubes. Proximal tubal obstruction is often not representative of true tubal obstruction but is rather an artifact of the test. Prior studies measuring the perceived pain and cramping during HSG have been conducted which have shown reduced pain scores and decreased uterine cramping when warmed contrast dye is used. The researchers propose that the use of warmed contrast media during HSG will be correlated with decreased pain scores and fewer cases of proximal tubal occlusion in women with otherwise normal uterine anatomy.",[31],"2026-07-28",{"date":186,"type":42},"2026-07-30",{"date":188,"type":23},"2026-09",{"date":190,"type":23},"2026-12",{"name":192,"class":49},"University of Oklahoma",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":24,"phases":203,"briefSummary":204,"conditions":205,"keywords":211,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100649521","phase-3-progesterone-luteal-support-in-unexplained-infertility-management-100649521","NCT07738068","Progesterone Luteal Support in Unexplained Infertility Management","PLUIM","Inclusion Criteria:\n\n* Primary or secondary infertility for at least a period of 1 year Participants whose previous pregnancy was achieved through MOH-IUI or IVF are eligible to join the study, provided they are willing to continue expectant management for at least six months before considering any further fertility interventions\n* Diagnosis of UI after infertility work-up, i.e.\n\n  * regular menstrual cycle ranging between 21-35 days,\n  * total motile sperm count ≥ 10 million\u002Fml,\n  * no risk of tubal pathology (or in case of increased risk, tubal pathology uitgesloten middels tubal patency testing)\n* A Hunault prognostic score ≥ 30% (calculated using the Hunault prediction model7, based on key prognostic factors including female age, subfertility duration, type of subfertility (primary or secondary), sperm motility and referral status),\n* Assignment to expectant management during at least six months, in accordance with Dutch NVOG Guidelines (4).\n* Female age ≥18 years old Female\n* BMI \\\u003C45 kg\u002Fm2\n\nExclusion Criteria:\n\n* Uncorrected uterine factors, such as endometrial polyps or submucosal fibroids,\n* Insufficient knowledge or understanding of the Dutch or English language and not willing or able to receive study information via a certified translator\n* Not able or willing to provide (written) informed consent\n* Contraindications for vaginal progesterone, in particular: females with allergy to peanuts or soya.\n* Formal diagnosis of endometriosis","43 Years",{"count":202,"type":23},640,[155],"The purpose of this study is to evaluate whether progesterone in women with unexplained infertility can increases live birth rate.\n\nThe main research question is:\n\nDoes luteal phase support with progesterone increase the live birth rate among couples with unexplained infertility?\n\nThe study compares progesterone with placebo to determine the effectiveness of progesterone in unexplained infertility.\n\nStudy participants will:\n\n* Perform home ovulation tests and maintain a digital diary to record menstrual cycles and study medication use.10\n* Take progesterone or placebo twice daily during the luteal phase of each menstrual cycle for up to six months.11\n* Continue usual medical care. No additional hospital visits or invasive procedures are required as part of the study.",[31,206,207,208,209,210],"Female Infertility","Subfertility","Infertility Primary","Infertility Secondary","Subfertility, Female",[212,213,214,215,216,217,218],"infertility","Unexplained Infertility","Luteal Phase Support (LPS)","Expectant Management","progesteron luteal support","progesteron","Progesterone (Utrogestan®)","2026-07-27",{"date":186,"type":42},{"date":222,"type":23},"2026-08-01",{"date":224,"type":23},"2031-01-01",{"name":226,"class":49},"Simone Broer",{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":234,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":4,"leadSponsor":254,"locationsCount":87},"100171064","inherited-reproductive-disorders-100171064","NCT01500447","Inherited Reproductive Disorders","The Molecular Basis of Inherited Reproductive Disorders","* INCLUSION CRITERIA:\n\nThe essential inclusion criteria include:\n\n1. failure to go through a normal, age-appropriate, spontaneous puberty and low sex steroid levels in the setting of low\u002Fnormal gonadotropins (due to substantial variability among patient presentations, this will be based on the clinical judgement of the Investigator), or\n2. abnormally early development of puberty, or\n3. normal puberty with subsequent development of low gonadotropin levels, or\n4. individuals with features indicating an increased risk of hypogonadotropic hypogonadism.\n5. Family members: both affected and unaffected family members are strongly encouraged to participate.\n\nEXCLUSION CRITERIA:\n\nSince hypogonadotropic hypogonadism is a rare condition, this protocol remains open to enrollment so that we may study all subjects that are both qualified and interested in participating.\n\nBecause HH represents a spectrum, where associated clinical findings may provide phenotypic clues to the assessment of inheritability and underlying physiology, exclusion criteria are very limited:\n\n* Patients who have additional pituitary deficiencies, effectively ruling out isolated GnRH deficiency, whether these deficiencies are congenital or acquired (e.g. secondary to malignancy, infection, or irradiation).\n* Patients who are taking medications known to affect GnRH secretion, such as corticosteroids or continuous opiate administration (or were taking them at the time of diagnosis).","ALL","6 Weeks","120 Years",{"count":238,"type":23},850,"Background:\n\n\\- During puberty, children begin to develop into adults. Problems with the hormones released during puberty can affect the reproductive system. Some people have low hormone levels that severely delay or prevent puberty. Others start puberty abnormally early. Other people may have a normal puberty but develop reproductive disorders later in life. Researchers want to study people with reproductive disorders to learn more about how these disorders may be inherited.\n\nObjectives:\n\n\\- To learn how reproductive system disorders may be inherited.\n\nEligibility:\n\n* People with one of the following problems:\n* Abnormally early puberty\n* Abnormally late or no puberty\n* Normal puberty with hormonal problems that develop later in life\n* People who have not yet had puberty but have symptoms that indicate low hormone levels.\n\nDesign:\n\n* Participants will provide a blood sample for testing. They will complete a questionnaire about their symptoms. They will also have a scratch-and-sniff test to study any problems with their ability to smell.\n* Participant medical records will be reviewed. Participants will also provide a family medical history.\n* Family members of those in the study may be invited to participate.\n* Treatment will not be provided as part of this study.",[241,31,242,243],"Genetic Disorder","Hypogonadism","Amenorrhea",[245,246,247,248,249,106],"Hypogonadotropic Hypogonadism","Kallmann Syndrome","Delayed Puberty","Hypothalamic Amenorrhea","Precocious Puberty","2026-07-25",{"date":184,"type":42},{"date":253,"type":42},"2012-04-25",{"name":255,"class":115},"National Institute of Environmental Health Sciences (NIEHS)",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":234,"minAge":4,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":87},"100648794","patient-empowerment-project-pep-study-100648794","NCT07725458","Patient Empowerment Project (PEP) Study","Efficacy of an Infertility Patient Empowerment Project (PEP), a Pilot Study","PEP","Patients seeking fertility treatment at participating clinics",{"count":22,"type":23},"The Patient Empowerment Project (PEP) will be integrated into the intake process at a fertility clinic to prepare clinical staff for any patient sensitivities or preferences and provide extra support if needed. The study will evaluate if the PEP increases patient retention and patient satisfaction scores.",[31,267],"Mental Health",[31,269,270],"Mental health","Assistive Reproductive Technology","2026-07-23",{"date":219,"type":42},{"date":44,"type":23},{"date":275,"type":23},"2027-08",{"name":143,"class":144},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":285,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":50},"100644889","endometrial-peristalsis-and-pregnancy-outcomes-in-hormone-replacement-therapy-hrt---frozen-embryo-transfer-fet-cycles-100644889","NCT07675213","Endometrial Peristalsis and Pregnancy Outcomes in Hormone Replacement Therapy (HRT) - Frozen Embryo Transfer (FET) Cycles","Correlation Between Endometrial Peristalsis And Pregnancy Outcomes In Patients Undergoing Frozen Embryo Transfer With Hormone Replacement Therapy for Endometrial Preparation Protocol","CONCO","Inclusion Criteria:\n\n* Women aged 18 - 42 years old\n* Scheduled for frozen embryo transfer cycles using hormone replacement therapy protocol\n* Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts\n* Provision of written informed consent to participate\n\nExclusion Criteria:\n\n* Having an allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Cycles with preimplantation genetic testing, oocyte donation, or in vitro maturation\n* Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus, endometrial polyp, large leiomyoma ≥5 cm in diameter, hydrosalpinx, endometrial hyperplasia)\n* Use of uterine relaxants or intralipid infusion during the embryo transfer process\n* Use of a GnRH-agonist for downregulation within one month",{"count":286,"type":23},442,"Endometrial peristalsis may influence embryo implantation and pregnancy outcomes, but its role during hormone replacement therapy (HRT)-prepared frozen embryo transfer (FET) cycles remains unclear. This prospective observational study will assess endometrial peristalsis at predefined time points during HRT-prepared FET cycles using transvaginal ultrasonography and evaluate its association with pregnancy outcomes. The study aims to clarify the clinical significance of endometrial peristalsis in HRT-prepared FET cycles and to provide evidence supporting endometrial assessment in assisted reproductive technology.",[31,65,66,67,68,69,289],"Hormone Replacement Therapy (HRT)",[71,72,73,74,76],"2026-07-08",{"date":293,"type":42},"2026-07-09",{"date":295,"type":42},"2026-06-30",{"date":84,"type":23},{"name":86,"class":49},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":234,"minAge":4,"maxAge":4,"enrollmentInfo":306,"targetDuration":308,"studyType":62,"phases":4,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":327},"100474142","food-intake-among-women-and-men-in-fertility-treatment-100474142","NCT05454046","Food Intake Among Women and Men in Fertility Treatment","Food & Fertility - Does Food Intake Affect Your Fertility?","Food&Fertility","Inclusion Criteria:\n\n* Women and men undergoing fertility treatment: in vitro fertilization (IVF), intracytoplasmatic sperm injection (ICSI), frozen-thawed embryo transfer (FET) or intrauterine insemination (IUI).\n* Availability of a semen sample analyzed 3 months before or after filling in the FFQ.\n* Read and understands Danish.\n\nExclusion Criteria:\n\n* Treatment with double donation (both semen and oocyte donation)",{"count":307,"type":23},4000,"10 Months","Worldwide infertility is highly prevalent and lifestyle factors, such as food intake, could have an essential role in the success of a fertility treatment. The literature is not consistent and adequate for recommendations to the increasing number of women and men of reproductive age who ask for lifestyle guidance. Therefore, the aims of the Food \\& Fertility study will be to investigate the association between food intake and semen quality, pregnancy- and live birth rates in women and men undergoing assisted reproductive technology (ART) treatment.",[31],[312,313,314,315,316,317,318],"Fertility","Assisted reproductive techniques","Food","Diet","Dietary supplements","Semen quality","Live birth","2026-07-07",{"date":291,"type":42},{"date":322,"type":42},"2022-08-01",{"date":324,"type":23},"2028-08-01",{"name":326,"class":49},"Aalborg University Hospital",8,{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":337,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":50},"100236569","phase-4-gnrh-for-luteal-support-in-ivficsifet-cycles-100236569","NCT02357654","GnRH for Luteal Support in IVF\u002FICSI\u002FFET Cycles","Inclusion Criteria:\n\n* women undergoing IVF\u002FICSI or frozen embryo transfers (FET) that less than 40 years old.\n\nExclusion Criteria:\n\n* day 3 transfers","40 Years",{"count":336,"type":23},350,[338],"PHASE4","During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .",[31],{"date":293,"type":42},{"date":343,"type":4},"2015-11",{"date":345,"type":23},"2026-07",{"name":347,"class":49},"University Reproductive Associates",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":50},"100646122","phase-4-ultra-long-gnrh-a-pretreatment-for-fet-outcomes-in-patients-with-deep-infiltrating-endometriosis-100646122","NCT07696351","Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis","A Randomized Controlled Study of Ultra-Long GnRH-a Pretreatment to Improve Frozen-Thawed Embryo Transfer Outcomes in Patients With Deep Infiltrating Endometriosis","DIE-GnRHa-FET","Inclusion Criteria:\n\n1. Female patients aged 18 to 39 years.\n2. Diagnosed with deep infiltrating endometriosis by ultrasound at the study center.\n3. Undergoing the first frozen-thawed embryo transfer cycle with hormone replacement therapy for endometrial preparation.\n4. Having at least one good-quality frozen embryo.\n5. Willing to participate in this randomized controlled study of GnRH-a pretreatment for deep infiltrating endometriosis and able to personally sign the written informed consent form.\n\nExclusion Criteria:\n\n1. Abnormal chromosomal karyotype.\n2. Other uterine diseases or conditions that may affect uterine cavity morphology or pregnancy outcomes, including intrauterine adhesions affecting the uterine cavity, intramural uterine fibroids, moderate to severe adenomyosis, congenital uterine malformation, endometrial tuberculosis, or endometrial thickness less than 8 mm on the transformation day.\n3. Recurrent implantation failure.\n4. Contraindications to hormone replacement therapy or long-acting GnRH-a treatment.\n5. Osteoporosis or depressed mood.\n6. Currently participating in another clinical study.\n7. Unable to adhere to study visits and follow-up, or planning to receive other treatment during the follow-up period.","39 Years",{"count":358,"type":23},120,[338],"Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endometrial receptivity, but its benefit before frozen-thawed embryo transfer remains uncertain.\n\nThis randomized controlled study will evaluate whether ultra-long GnRH-a pretreatment before hormone replacement therapy improves clinical pregnancy outcomes in patients with deep infiltrating endometriosis undergoing their first frozen-thawed embryo transfer cycle. Eligible participants will be randomly assigned to either the GnRH-a pretreatment group or the control group. Participants in the GnRH-a group will receive two injections of long-acting GnRH-a before hormone replacement therapy for endometrial preparation, while participants in the control group will receive routine hormone replacement therapy alone.\n\nThe primary outcome is clinical pregnancy rate, defined as the presence of a gestational sac on transvaginal ultrasound 30 ± 3 days after embryo transfer. Secondary outcomes include implantation rate, ectopic pregnancy rate, early spontaneous abortion rate, ongoing pregnancy rate at 12 weeks of gestation, and delivery rate. Safety will be evaluated by recording adverse events after GnRH-a injection. The planned enrollment is 120 participants.",[362,31],"Deep Infiltrating Endometriosis (DIE)",[364,365,366,367,368,369,31],"Deep infiltrating endometriosis","GnRH-a","Triptorelin","Frozen-thawed embryo transfer","Hormone replacement therapy","Clinical pregnancy rate","2026-07-06",{"date":372,"type":42},"2026-07-10",{"date":374,"type":42},"2025-08-01",{"date":376,"type":23},"2027-07-31",{"name":378,"class":49},"Li-jun Ding",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":17,"sex":234,"minAge":19,"maxAge":20,"enrollmentInfo":386,"targetDuration":4,"studyType":24,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":87},"100560739","automation-of-the-in-vitro-fertilization-laboratory-100560739","NCT06581068","Automation of the In Vitro Fertilization Laboratory","Automation of the In Vitro Fertilization Laboratory: A Validation Study","Inclusion Criteria:\n\n* Informed consent signed by the patients before treatment.\n* Medical indication to perform assisted reproductive technology.\n* Body mass index between 20 and 29 kg\u002Fm2 (female participants only).\n* For women with indication of utilizing autologous eggs:\n\n  * Anti-Müllerian Hormone (AMH) value of at least 1.5 ng\u002FmL.\n  * 18 - 39 years of age.\n* For women utilizing donor eggs (egg donor age 18-28 years):\n\n  * 18 - 45 years of age.\n\nExclusion Criteria:\n\n* Patients diagnosed with recurrent pregnancy loss.\n* Inaccessible ovaries for puncture.\n* History of total or partial fertilization failure in a previous fertility treatment.\n* History of repeated implantation failure defined as three previous unsuccessful embryo transfers.\n* Uterine factors (e.g. fibroids, uterine surgeries, Müllerian malformations) at the discretion of the medical team and based on its impact on success and\u002For risk to the patient or the pregnancy may compromise treatment prognosis).\n* Untreated hydrosalpinx\n* Severe endometriosis III, IV, presence of endometriomas and\u002For history of endometrioma resection.\n* Polycystic ovarian syndrome.\n* Patients with any of the following severe male factor infertility:\n\n  * Sperm concentrations less than 5 million per mL\n  * Progressive motility less than 5%\n  * Others (e.g, globozoospermia and seminal infections) at the discretion of the medical team and based on its impact on success.\n  * Surgically retrieved sperm (TESE, MESA, PESA)\n* Pre-existing conditions compromising reproductive (e.g., thrombophilia, chronic degenerative and autoimmune diseases, uncontrolled hormonal disorders).\n* Any other case of abnormalities that could compromise success rates according to the criteria of clinical personnel in charge.\n* Inability to adhere to the medical protocols and\u002For schedules for personal reasons.\n* Intercurrent medical disorder",{"count":387,"type":23},150,[26],"Enrolled patients will undergo an Assisted Reproductive technology (ART) treatment using intracytoplasmic sperm injection (ICSI, the direct injection of a single sperm cell into an oocyte) as the method of insemination. In this prospective cohort study, patients' sperm, eggs, and embryos will be processed using an automated system called AURA (Conceivable Life Sciences), which consists of five subsystems. Specifically, sperm samples will be prepared for fertilization using the subsystem C:SPERM. Cumulus-oocyte complexes (COCs) containing the oocytes will be isolated from follicular fluid using the subsystem C:EGG. One out of every four COCs will be removed from the AURA system at random and processed according to the local treatment clinic's standard operating procedure. All other COCs will continue automated procedures and will be denuded, fertilized, incubated, and vitrified using the AURA subsystems C:EGG. C:ICSI, C:CULTURE and C:VIT, respectively. All automated procedures will be conducted under the supervision of a laboratory manager, who can intervene, address any potential anomalies, and override any steps undertaken by the automated AURA system. The study aims to deliver a descriptive evaluation of the AURA system, including assessing the device's performance, defined by its level of automation, efficiency, and throughput. As a secondary objective, the study aims to characterize the clinical performance of each of AURA's subsystems and correlate this performance against pre-established benchmarks in a non-inferiority statistical analysis. Finally, the study seeks to collect technical data related to AURA's hardware and software operation.",[31,391],"ART","2026-07-02",{"date":370,"type":42},{"date":395,"type":42},"2024-12-03",{"date":397,"type":23},"2027-04",{"name":399,"class":144},"Conceivable Life Sciences",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":408,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":24,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":419,"locationsCount":421},"100646591","phase-4-embryo-quality-in-ovarian-stimulation-with-hmg-100646591","NCT07691073","Embryo QUAlity in Ovarian Stimulation With hMG.","The Impact of Ovarian Stimulation With hMG on Embryo Quality in Advanced Age Women. A Randomized Controlled Trial","EQUAM","Inclusion Criteria:\n\n* Undergoing preimplantation genetic screening cycles\n* AMH 0.5 - 3.5 ng\u002Fml or AFC 5-20 (results of up to one year will be valid)\n* BMI 18.5 - 30 Kg\u002Fm2\n* Normal karyotypes in both partners\n\nExclusion Criteria:\n\n* Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria\n* Severe male factor requiring TESE (testicular sperm extraction)\n* Administration of any other drug potentially interfering with the treatment\n* Contraindication for hormonal treatment\n* Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment)\n* Monogenic disease to be detected with PGT-M\n* Biochemical and\u002For ultrasonographic evidence of polycystic ovarian syndrome\n* Endocrinological and\u002For autoimmune disorders","38 Years","41 Years",{"count":179,"type":23},[338],"Ovarian stimulation (OS) is a key component of IVF, aimed at increasing oocyte yield and improving embryo development potential. While early protocols relied solely on FSH, newer approaches incorporate hMG and LH-based stimulation, allowing more individualized treatments for specific patient populations. Evidence suggests that hMG and recombinant FSH (rFSH) have comparable effectiveness in stimulation outcomes, and current guidelines support the use of both. However, the impact of different gonadotropins on embryo quality remains unclear, with mixed findings across protocols. Given the increasing use of combined rFSH and hMG and the limited data in PPOS protocols, this study proposes a randomized controlled trial to compare embryo quality between two different rFSH-hMG dosing strategies.",[31],"2026-07-01",{"date":291,"type":42},{"date":188,"type":23},{"date":418,"type":23},"2029-05",{"name":420,"class":49},"Fundacion Dexeus",4,{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":24,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":87},"100635739","ultra-rapid-blastocyst-vitrification-pilot-randomized-study-100635739","NCT07556601","Ultra-rapid Blastocyst Vitrification: Pilot Randomized Study","Clinical Validation of Ultra-rapid Blastocyst Vitrification: a Randomized Pilot Study in Oocyte Donation Cycles","Inclusion Criteria:\n\n* Recipients of donor oocytes\n* Blastocysts suitable for cryopreservation\n\nExclusion Criteria:\n\n* Cycles involving PGT\n* Cycles not reaching blastocyst stage.","50 Years",{"count":431,"type":23},80,[26],"Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.",[31],"2026-06-29",{"date":295,"type":42},{"date":438,"type":42},"2026-06-01",{"date":440,"type":23},"2028-03",{"name":420,"class":49},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":449,"minAge":450,"maxAge":20,"enrollmentInfo":451,"targetDuration":4,"studyType":24,"phases":453,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100646920","effect-of-varicocelectomy-on-spermatogenic-cell-count-and-semen-parameters-100646920","NCT07684963","Effect of Varicocelectomy on Spermatogenic Cell Count and Semen Parameters","Seminal Spermatogenic Cell Count Pre and Post Varicocelectomy: Relation to Seminal Parameters","Inclusion Criteria:\n\n* Infertile married males diagnosed with clinical varicocele.\n* Age between 20-45 years.\n* Patients indicated for varicocelectomy according to standard clinical guidelines.\n* Abnormal or suboptimal semen parameters on at least two semen analyses.\n\nExclusion Criteria:\n\n* Azoospermic patients (complete absence of sperm in semen).\n* History of previous varicocelectomy or scrotal surgery.\n* Presence of other known causes of infertility (e.g., genetic abnormalities, obstructive azoospermia).\n* Active genital infection or systemic infection affecting semen analysis.\n* Use of medications affecting spermatogenesis within the last 3 months (e.g., testosterone, chemotherapy).\n* Chronic systemic diseases known to affect fertility (e.g., uncontrolled diabetes, liver failure).\n* Severe leukocytospermia as confirmed by peroxidase (Endtz) test exceeding WHO reference limits.\n* Pus cell \\> 1 million\u002Fml by peroxidase.","MALE","20 Years",{"count":452,"type":23},40,[26],"This study aims to evaluate how varicocele surgery (varicocelectomy) affects the number of immature sperm cells (spermatogenic cells) found in the semen of infertile men. Varicocele, an abnormal dilation of veins in the scrotum, is a common cause of male infertility that can negatively impact semen quality and overall testicular function. While surgery is widely performed to improve standard semen parameters, this study specifically investigates its impact on the shedding of immature germ cells into the seminal fluid, which can be an indicator of impaired sperm production.\n\nResearchers will enroll 40 infertile married men, aged 20 to 45, who have been diagnosed with a clinical varicocele and exhibit abnormal semen parameters. All participants will undergo a single surgical intervention known as a subinguinal microsurgical varicocelectomy. To measure the effects of the surgery, participants will undergo careful semen analysis before the procedure, and again at 3 and 6 months postoperatively. The primary goal is to track changes in the spermatogenic cell count and abnormal sperm morphology, and to explore how these changes correlate with conventional semen parameters like sperm concentration, motility, and vitality.",[456,457,31,458],"Varicocele","Male Infertility","Varicocelectomy",[460,461,462,463,464,465],"Spermatogenic Cells","Semen Parameters","Immature Germ Cells","Semen Analysis","Sperm Morphology","Round Cells","2026-06-28",{"date":370,"type":42},{"date":44,"type":23},{"date":470,"type":23},"2027-09",{"name":472,"class":49},"Assiut University",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":234,"minAge":450,"maxAge":20,"enrollmentInfo":480,"targetDuration":4,"studyType":24,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":87},"100629736","safety-evaluation-of-the-hypersperm-sperm-preparation-procedure-for-in-vitro-fertilization-100629736","NCT07478549","Safety Evaluation of the HyperSperm Sperm Preparation Procedure for In Vitro Fertilization","Prospective, Multicenter, Randomized Clinical Trial Evaluating the Safety of the HyperSperm Sperm Preparation Procedure.","Inclusion Criteria:\n\nGeneral\n\n* Couples undergoing in vitro fertilization (IVF) treatment.\n* Planned use of fresh sperm samples obtained by masturbation.\n\nFemale\n\n* Age between 20 and 42 years.\n* Antral follicle count ≥ 4.\n* Eligible for ovarian stimulation and embryo transfer.\n\nMale\n\n* Age between 20 and 45 years.\n* Fresh semen sample (not cryopreserved).\n* Pre-processing sperm concentration ≥ 5 × 10⁶ sperm\u002FmL.\n\nExclusion Criteria:\n\nGeneral\n\n* Active sexually transmitted infection (STI).\n* Use of donor sperm.\n* Medical conditions contraindicating pregnancy or the IVF procedure.\n\nFemale\n\n* Uterine anomalies associated with distortion of the uterine cavity.\n* Absence of one ovary or functional disorders preventing ovulation.\n* Diabetes mellitus or other metabolic disorders.\n* Recurrent pregnancy loss, defined as more than two clinical pregnancies without live birth.\n\nMale\n\n\\- Any medical condition affecting semen quality that, in the investigator's opinion, may interfere with study participation.",{"count":481,"type":23},202,[26],"Prospective, multicenter, randomized clinical study evaluating the safety of a novel sperm preparation method for in vitro fertilization (IVF), compared to standard sperm preparation procedures.",[31],"2026-06-23",{"date":487,"type":42},"2026-06-26",{"date":190,"type":23},{"date":490,"type":23},"2028-05",{"name":492,"class":49},"Fecundis Lab SL",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":4},"100644155","outcomes-of-embryos-created-from-abnormally-fertilized-oocytes-100644155","NCT07666243","Outcomes of Embryos Created From Abnormally Fertilized Oocytes","Inclusion Criteria:\n\n* Underwent in vitro fertilization which resulted in a blastocyst derived from an abnormally fertilized embryo",{"count":500,"type":23},92,"The purpose of this study is to retrospectively analyze data from multiple clinics in a fertility network on embryos that were created from abnormally fertilized oocytes (AFO) including the rate of transfers and any clinical outcomes in order to inform providers in their decision making regarding AFOs.",[503,31],"Abnormal Fertilization",[312,505],"Reproductive Medicine","2026-06-22",{"date":508,"type":42},"2026-06-24",{"date":510,"type":23},"2026-06",{"date":512,"type":23},"2027-06",{"name":143,"class":144},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":24,"phases":525,"briefSummary":526,"conditions":527,"keywords":532,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":50},"100528791","hyaluronan-enriched-medium-and-euploid-blastocyst-transfers-100528791","NCT06165367","Hyaluronan-enriched Medium and Euploid Blastocyst Transfers","Impact of Hyaluronan-enriched Medium on Pregnancy Outcomes Following Euploid Blastocyst Transfers","GluePloid","Inclusion Criteria:\n\n* All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.\n* Rank of randomization based on embryo quality.\n* Only hormonal replacement theraphy (HRT) cycle regimen.\n* Women aged 18 years to 46 years.\n* Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.\n* All sperm samples.\n* BMI between 18 and 35.\n\nExclusion Criteria:\n\n* FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).\n* FET cycles with mosaic \u002F aneuploid blastocysts.\n* FET cycles with unknown outcome.\n* FET cycles with Day 6 or Day 7 biopsied blastocysts.\n* FET with patients' endometrium preparation with treatments other than HRT.\n* FET where PGT-A was performed for gender selection.","46 Years",{"count":524,"type":23},783,[26],"It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule. However, none of previous studies included preimplantation genetic testing for aneuploidy (PGT-A) embryos. In order to investigate the impact of this hyaluronan-enriched on pregnancy outcomes, it is essential to evaluate its efficacy on euploid-only embryo transfers. The aim of the present study is to evaluate whether a short period of exposure of euploid blastocysts to EmbryoGlue prior to and during transfer positively impact on pregnancy outcomes of frozen embryo transfer (FET) cycles.",[31,528,529,530,531,134],"Implantation Rate","Clinical Pregnancy Rate","Live Birth Rate","Blastocysts",[533,132,534,535,536,537,538,539,540,541],"HRT","Next-generation sequencing (NGS)","Miscarriage rate","single embryo transfer (SET)","EmbryoGlue","BMI","Embryo quality","Hyaluronan-enriched medium","Transfer medium",{"date":543,"type":42},"2026-06-25",{"date":545,"type":42},"2024-01-15",{"date":547,"type":23},"2026-12-31",{"name":549,"class":49},"ART Fertility Clinics LLC",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":449,"minAge":19,"maxAge":20,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":559,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":50},"100644208","effects-of-visceral-osteopathic-massage-on-semen-parameters-and-hemodynamics-factors-in-varicocele-100644208","NCT07665905","Effects of Visceral Osteopathic Massage on Semen Parameters and Hemodynamics Factors in Varicocele","Investigation of the Effects of Visceral Osteopathic Massage Techniques on Semen Parameters and Hemodynamic Factors in Men With Varicocele: A Randomized Controlled Study","Inclusion Criteria:\n\n1. Male individuals aged 18-45 years.\n2. Diagnosis of varicocele confirmed by clinical examination and Doppler Ultrasound.\n3. Not being considered a candidate for surgery by a urology specialist.\n4. Following a follow-up protocol based on spermiogram results.\n5. Having at least one varicocele-related abnormality in spermiogram parameters according to WHO 2021 standards.\n6. Providing voluntary consent to participate in the study.\n\nExclusion Criteria:\n\n1. History of prior inguinal or scrotal surgery.\n2. Presence of active urogenital infection or malignancy.\n3. History of spinal or abdominal surgery that would contraindicate complementary medicine interventions.\n4. Having systemic inflammatory, rheumatologic, or endocrinologic diseases.\n5. Receiving additional medical or surgical intervention during the study period beyond routine medical treatment.\n6. Sperm quality changes due to hypogonadotropic causes.\n7. Use of prescribed purified flavonoid fraction venotonics for venous congestion and endothelial dysfunction.\n8. Use of antioxidant supplements (e.g., L-carnitine, L-acetylcarnitine, Ubiquinol, etc.) intended to improve sperm quality.\n9. Refusal to participate in the study.",{"count":558,"type":23},32,[26],"The project aims to evaluate the effects of a visceral osteopathic manual therapy (VOM) protocol on semen parameters and testicular hemodynamic indicators in men diagnosed with varicocele. Varicocele, the most common correctable cause of male infertility, is a progressive vascular pathology characterized by dilation of the pampiniform plexus veins and venous reflux. Multifactorial mechanisms such as venous valve insufficiency, increased intra-abdominal pressure, microcirculatory impairment, and oxidative stress play a role in the pathophysiology of varicocele. Therefore, the present study investigates the clinical effectiveness of a non-invasive rehabilitation approach aimed at regulating intra-abdominal pressure and improving pelvic venous drainage. The study will be conducted using a prospective, randomized controlled clinical design, including male participants aged 18-45 years diagnosed with varicocele. The intervention group will receive visceral osteopathic manual therapy techniques two times per week for eight weeks, while the control group will receive lifestyle recommendations only. Before and after the intervention, semen analysis results, sperm morphology, motility parameters, and testicular venous hemodynamic measurements obtained by color Doppler ultrasonography will be compared. Parametric and non-parametric statistical methods will be used in the analyses.\n\nThis project aims to generate clinical evidence regarding conservative, complementary medicine-based treatment options in the field of male infertility. Compared to studies on female reproductive health, research focusing on male reproductive health is more limited; therefore, this study is expected to contribute to the literature in this area. The results are anticipated to support the development of a cost-effective and accessible model for infertility treatment processes. In addition, the project aims to provide scientific data for the development of sustainable reproductive health approaches in terms of health economics in Türkiye. The study seeks to determine the effects of visceral osteopathic manual therapy on varicocele-related semen parameters and hemodynamic variables and to contribute to the development of new evidence-based approaches in the management of male infertility.",[456,31],[563,456,31,564],"Osteopathic Physicians","Men's Health","2026-06-18",{"date":508,"type":42},{"date":568,"type":23},"2026-09-01",{"date":570,"type":23},"2027-11-01",{"name":572,"class":49},"Ankara Yildirim Beyazıt University",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":449,"minAge":19,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":24,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":594,"locationsCount":50},"100598632","intelliwell-an-ai-assisted-imaging-platform-for-detection-and-location-of-ultra-rare-testicular-sperm-in-surgical-specimens-100598632","NCT07074015","IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens","IntelliWell: An AI-Assisted Microwell Platform for Label-Free Localization of Ultra-Rare Sperm in Non-Obstructive Azoospermia Micro-TESE Specimens","Inclusion Criteria:\n\n1. Male subjects presenting to Brigham and Women's or Faulkner urology clinic with infertility with clinical non-obstructive azoospermia (clinical diagnosis based on two semen analyses, physical examination, and hormonal testing).\n2. Male subjects undergoing micro-surgical testicular sperm extraction surgery at Brigham and Women's Hospital.\n3. Surgically extracted sperm which are not found to have clinically usable quantities of sperm after standard of care manual processing for which samples would otherwise be discarded and the procedure deemed unsuccessful.\n\nExclusion Criteria:\n\n1\\. Female subject (with whom male subjects intends to conceive with surgically extracted sperm) cannot or will not provide her informed consent for study participation. She will undergo ICSI at BWH with BWH embryology.",{"count":581,"type":23},20,[26],"This study will help determine whether an AI-assisted microwell platform (IntelliWell) can identify rare sperm cells in testicular samples found to not have sperm by conventional analysis. Instead of discarding testicular tissue which was found to be non-sperm bearing by conventional analysis the testicular tissue will be processed using IntelliWell and, if sperm is found and verified by embryologists, it may be used for intracytoplasmic sperm injection (ICSI).",[31,585],"Azoospermia",[212,587,588],"azoospermia","micro-TESE","2026-06-17",{"date":506,"type":42},{"date":592,"type":42},"2026-04-16",{"date":84,"type":23},{"name":595,"class":49},"Brigham and Women's Hospital",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":234,"minAge":19,"maxAge":602,"enrollmentInfo":603,"targetDuration":4,"studyType":24,"phases":605,"briefSummary":606,"conditions":607,"keywords":610,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":50},"100643177","a-large-scale-prospective-cohort-study-was-conducted-to-explore-the-association-between-environmental-exposure-and-behavioral-factors-and-infertility-the-success-rate-of-assisted-reproductive-technology-100643177","NCT07641387","A Large-scale, Prospective Cohort Study Was Conducted to Explore the Association Between Environmental Exposure and Behavioral Factors and Infertility (the Success Rate of Assisted Reproductive Technology)","Inclusion Criteria:\n\n* 1\\. Women aged 18 to 46 who use their own eggs or men aged 18 to 55 who use their own sperm; 2. Patients who meet the diagnostic criteria for infertility; 3. Clarify the medical history of persistent infertility for a certain period of time; 4. Voluntarily participate in the project and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Artificial insemination population with any of the following ARTs contraindications: a. Impairment of sperm and egg combination caused by fallopian tube factors on the female side. b. The female side suffers from acute infection of the reproductive and urinary system or sexually transmitted diseases. c. The female side suffers from genetic diseases, serious physical diseases, and mental and psychological disorders. d. There is a history of birth of babies with congenital defects and it is confirmed that it is caused by female factors. e. The female side is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. f. The female side has bad habits such as alcoholism and drug abuse.\n\n  2\\. First-generation test-tube baby and second-generation test-tube baby population with any of the following ARTs contraindications: a. Any party who provides gametes suffers from acute infection of the reproductive and urinary systems and sexually transmitted diseases or has bad habits such as alcoholism and drug abuse. b. Any party who provides gametes is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. c. The couple who received embryo donation\u002Fegg donation suffers from acute infection of reproductive and urinary system and sexually transmitted diseases, or has bad habits such as alcoholism and drug abuse. d. The woman's uterus is not capable of pregnancy or has a serious physical disease that cannot withstand pregnancy.\n\n  3\\. No embryo transfer after egg retrieval; 4. Frozen embryo transfer is received more than 180 days after egg retrieval.","55 Years",{"count":604,"type":23},5000,[26],"The aim is to explore the reasons for the failure of assisted reproductive technology (ART) in infertile patients in Hunan Province and seek ways to improve the success rate of ART. The study will focus on how environmental exposure (such as environmental pollutants related to plastic products) and lifestyle and social factors affect the success rate of ART in infertile patients.\n\nIn order to explore these issues in depth, the study plans to collect 5,000 samples (male: female ratio 1:1), screen the research subjects from infertile patients who visited Xiangya Third Hospital in Changsha, Hunan Province, and establish a large-scale, prospective infertility patient cohort. By collecting multi-faceted information of the research subjects, including sociodemographic characteristics, lifestyle, basic health status, etc., and conducting long-term follow-up observations, the ART live birth situation of infertile patients is analyzed.\n\nIn terms of research methods, a multivariate analysis method will be used to explore the association between various factors and ART success rate, and a risk prediction model will be constructed. In addition, the study also hopes to clarify the specific reasons for the failure of infertile patients to receive ART, provide a scientific basis for clinical decision-making, and provide guidance for the formulation of environmental protection policies and the improvement of public reproductive health literacy.\n\nIn general, this study, through a large-scale, prospective cohort study, deeply explores the various factors that affect the success rate of ART in infertile patients, and strives to build a risk prediction model in order to improve the success rate of ART and bring more hope to infertile families.",[31,608,609],"Infertility Assisted Reproductive Technology","Infertility (IVF Patients)",[611,612,613,614,615,616],"environmental pollutants","Assisted Reproductive Technology","prospective cohort","life-style","risk factor","social factor","2026-06-08",{"date":619,"type":42},"2026-06-11",{"date":621,"type":42},"2025-04-01",{"date":623,"type":23},"2035-04-01",{"name":625,"class":49},"The Third Xiangya Hospital of Central South University",{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":633,"targetDuration":4,"studyType":24,"phases":635,"briefSummary":636,"conditions":637,"keywords":640,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":656,"leadSponsor":658,"locationsCount":50},"100638756","theta-healing-based-intervention-in-women-with-polycystic-ovary-syndrome-100638756","NCT07630441","Theta Healing-Based Intervention in Women With Polycystic Ovary Syndrome","The Effect of a Theta Healing-Based Intervention on Fertility Anxiety, Body Self-Compassion, and Body Image in Women Diagnosed With Polycystic Ovary Syndrome: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18-45 years\n* Diagnosed with Polycystic Ovary Syndrome (PCOS)\n* Able to read and understand Turkish\n* Voluntary participation in the study\n* Access to a smartphone and internet connection\n\nExclusion Criteria:\n\n* Diagnosed psychiatric disorder\n* Participation in another psychological intervention program\n* Any health condition preventing participation in the intervention sessions\n* Incomplete questionnaire responses",{"count":634,"type":23},142,[26],"This randomized controlled study aims to evaluate the effect of a Theta Healing-based intervention on fertility concerns, self-compassion, and body image in women diagnosed with Polycystic Ovary Syndrome (PCOS). Participants will be randomly assigned to intervention and control groups. The intervention group will receive a structured 5-day Theta Healing-based online intervention program, while the control group will continue routine care. Outcome measures will be assessed at baseline and 6 weeks after the intervention.",[638,31,639],"Polycystic Ovarian Syndrome (PCOS)","Psychological Stress",[641,642,643,644,645,646,647,648,649,650,651],"PCOS","POLYCYSTIC OVARY SYNDROME","THETA HEALING","SELF-COMPASSION","BODY IMAGE","COMPLEMENTARY THERAPY","MEDITATION","REPRODUCTIVE HEALTH","Women's Health","Mind-Body Intervention","fertility anxiety","2026-06-03",{"date":654,"type":42},"2026-06-05",{"date":617,"type":23},{"date":657,"type":23},"2026-09-15",{"name":659,"class":49},"Ankara Medipol University",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":429,"enrollmentInfo":667,"targetDuration":4,"studyType":24,"phases":669,"briefSummary":670,"conditions":671,"keywords":672,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":50},"100286671","phase-3-fertility-preservation-using-tamoxifen-and-letrozole-in-estrogen-sensitive-tumors-trial-100286671","NCT03011684","Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial","TALES","Inclusion Criteria:\n\n* New breast cancer diagnosis\n* Has not yet begun chemotherapy\n* Desires to undergo ovarian stimulation and oocyte retrieval prior to cancer treatment\n* Age 18 years old or greater\n\nExclusion Criteria:\n\n* Chemotherapy has already commenced or been completed\n* History of recurrent breast cancer (with a prior history of chemotherapy)\n* Stage IV breast cancer diagnosis (metastases remote from the breast)\n* Patient's oncologist advises against the trial - in which case they can choose to receive stimulation with letrozole+gonadotropin\n* Does not plan to undergo ovarian stimulation and oocyte retrieval prior to diagnosis\n* Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow-up, or interpretation of study results\n* Age less than 18 years old",{"count":668,"type":23},309,[155],"Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decision-related regret in cancer survivors. Though letrozole plus gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to improved oocyte yield. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.",[31],[673,674],"Fertility Preservation","Breast Cancer","2026-06-02",{"date":677,"type":42},"2026-06-04",{"date":679,"type":42},"2016-07-21",{"date":681,"type":23},"2028-03-31",{"name":683,"class":49},"University of California, San Francisco"]